Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

NCT04287829 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Mesotheliomas Pleural

Interventions

DRUG: Pembrolizumab
DRUG: Lenvatinib

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]